Vemurafenib Suspended Phase 1 Trials for Advanced or Inoperable Malignant Melanoma With BRAF Mutation Treatment

IndicationsStatusPurposePhase
SuspendedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01841463Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation